195 related articles for article (PubMed ID: 29527479)
1. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.
Minkova L; Gregory S; Scahill RI; Abdulkadir A; Kaller CP; Peter J; Long JD; Stout JC; Reilmann R; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
Neuroimage Clin; 2018; 17():312-324. PubMed ID: 29527479
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
[TBL] [Abstract][Full Text] [Related]
3. Early grey matter changes in structural covariance networks in Huntington's disease.
Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
[TBL] [Abstract][Full Text] [Related]
4. Structural brain correlates of dementia in Huntington's disease.
Martinez-Horta S; Sampedro F; Horta-Barba A; Perez-Perez J; Pagonabarraga J; Gomez-Anson B; Kulisevsky J
Neuroimage Clin; 2020; 28():102415. PubMed ID: 32979842
[TBL] [Abstract][Full Text] [Related]
5. White and Gray Matter Abnormalities in Manifest Huntington's Disease: Cross-Sectional and Longitudinal Analysis.
Sweidan W; Bao F; Bozorgzad NS; George E
J Neuroimaging; 2020 May; 30(3):351-358. PubMed ID: 32128927
[TBL] [Abstract][Full Text] [Related]
6. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance.
Minkova L; Eickhoff SB; Abdulkadir A; Kaller CP; Peter J; Scheller E; Lahr J; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
Hum Brain Mapp; 2016 Jan; 37(1):67-80. PubMed ID: 26453902
[TBL] [Abstract][Full Text] [Related]
7. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.
Scahill RI; Hobbs NZ; Say MJ; Bechtel N; Henley SM; Hyare H; Langbehn DR; Jones R; Leavitt BR; Roos RA; Durr A; Johnson H; Lehéricy S; Craufurd D; Kennard C; Hicks SL; Stout JC; Reilmann R; Tabrizi SJ;
Hum Brain Mapp; 2013 Mar; 34(3):519-29. PubMed ID: 22102212
[TBL] [Abstract][Full Text] [Related]
8. Microstructural brain abnormalities in Huntington's disease: A two-year follow-up.
Odish OF; Leemans A; Reijntjes RH; van den Bogaard SJ; Dumas EM; Wolterbeek R; Tax CM; Kuijf HJ; Vincken KL; van der Grond J; Roos RA
Hum Brain Mapp; 2015 Jun; 36(6):2061-74. PubMed ID: 25644819
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal atrophy characterization of cortical and subcortical gray matter in Huntington's disease patients.
Ramirez-Garcia G; Galvez V; Diaz R; Bayliss L; Fernandez-Ruiz J; Campos-Romo A
Eur J Neurosci; 2020 Apr; 51(8):1827-1843. PubMed ID: 31705594
[TBL] [Abstract][Full Text] [Related]
10. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.
Novak MJ; Warren JD; Henley SM; Draganski B; Frackowiak RS; Tabrizi SJ
Brain; 2012 Apr; 135(Pt 4):1165-79. PubMed ID: 22505631
[TBL] [Abstract][Full Text] [Related]
11. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: a three-year follow-up study.
Odish OF; van den Berg-Huysmans AA; van den Bogaard SJ; Dumas EM; Hart EP; Rombouts SA; van der Grond J; Roos RA;
Hum Brain Mapp; 2015 Jan; 36(1):110-9. PubMed ID: 25139578
[TBL] [Abstract][Full Text] [Related]
13. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.
Coppen EM; Jacobs M; van den Berg-Huysmans AA; van der Grond J; Roos RAC
Parkinsonism Relat Disord; 2018 Jan; 46():56-61. PubMed ID: 29128164
[TBL] [Abstract][Full Text] [Related]
14. Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.
Chen L; Hua J; Ross CA; Cai S; van Zijl PCM; Li X
J Neurosci Res; 2019 Apr; 97(4):467-479. PubMed ID: 30489648
[TBL] [Abstract][Full Text] [Related]
15. Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study.
Johnson EB; Parker CS; Scahill RI; Gregory S; Papoutsi M; Zeun P; Osborne-Crowley K; Lowe J; Nair A; Estevez-Fraga C; Fayer K; Rees G; Zhang H; Tabrizi SJ;
EBioMedicine; 2021 Mar; 65():103266. PubMed ID: 33706250
[TBL] [Abstract][Full Text] [Related]
16. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.
Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J
J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716
[TBL] [Abstract][Full Text] [Related]
17. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.
Hobbs NZ; Henley SM; Ridgway GR; Wild EJ; Barker RA; Scahill RI; Barnes J; Fox NC; Tabrizi SJ
J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):756-63. PubMed ID: 19955112
[TBL] [Abstract][Full Text] [Related]
18. Gray matter atrophy in presymptomatic Huntington's patients.
Király A; Kincses ZT; Szabó N; Tóth E; Csete G; Faragó P; Vécsei L
Ideggyogy Sz; 2016 Jul; 69(7-8):261-267. PubMed ID: 29465891
[TBL] [Abstract][Full Text] [Related]
19. Striatal gray matter loss in Huntington's disease is leftward biased.
Mühlau M; Gaser C; Wohlschläger AM; Weindl A; Städtler M; Valet M; Zimmer C; Kassubek J; Peinemann A
Mov Disord; 2007 Jun; 22(8):1169-73. PubMed ID: 17394246
[TBL] [Abstract][Full Text] [Related]
20. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
